Company intelligence / Profile preview

Allinaire Therapeutics

Cleveland, Ohio, United Statesallinaire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies for the treatment of COPD and PAH. Their therapeutic approach aims to address lung inflammation and airway remodeling that lead to COPD, potentially offering a disease-modifying treatment rather than just symptomatic relief[1][7].

Therapeutic areas: PulmonologyCardiovascular
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

anti-EMAP II antibody

Pre-clinical

Indications: Pulmonary arterial hypertension, Chronic obstructive pulmonary disease, Viral-induced acute lung injury

Partnerships

BioMotivIndiana University Research and Technology Corp.Chiesi Farmaceutici S.p.A.

Beyond the preview

Go deeper on Allinaire Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allinaire Therapeutics.

Explore the full profile